Vimarsana
Biggest News Aggregation in the World

Page 18 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - Vimarsana News

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers - Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medic...

KEYTRUDA® Plus LENVIMA® Demonstrated Superior Progression-Free Survival and Overall Survival Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma - Vimarsana News

KEYTRUDA® Plus LENVIMA® Demonstrated Superior Progression-Free Survival and Overall Survival Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study Presented at 2021 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine … KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib ...

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination - Vimarsana News

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA Â...

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU - Vimarsana News

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results News provided by Share this article Share this article RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposiu...

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa - Vimarsana News

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed publication Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in Dr. David Ho's Columbia University lab and Regeneron scientists have independently confirmed that REGEN-COV TM (casirivimab and imdevimab antibody cocktail) successfully neutralizes the circulating SARS-CoV-2 variants first identified in the UK (B.1.1.7) and South Africa (B.1.351). Columbia's findings were included in a paper posted to bioRxiv and submi...